Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Lyell Immunopharma Inc (NASDAQ: LYEL) was $0.54 for the day, down -8.83% from the previous closing price of $0.59. In other words, the price has decreased by -$8.83 from its previous closing price. On the day, 0.62 million shares were traded. LYEL stock price reached its highest trading level at $0.6118 during the session, while it also had its lowest trading level at $0.5365.
Ratios:
Our analysis of LYEL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.06 and its Current Ratio is at 7.06. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on October 30, 2024, Downgraded its rating to Underperform and sets its target price to $1 from $6 previously.
On June 27, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $1.
JP Morgan Downgraded its Overweight to Neutral on August 28, 2023, whereas the target price for the stock was revised from $15 to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 21 ’25 when Ramachandra Sumant bought 200,000 shares for $0.58 per share. The transaction valued at 115,220 led to the insider holds 200,000 shares of the business.
Klausner Richard bought 158,000 shares of LYEL for $94,942 on Mar 14 ’25. The Director now owns 843,365 shares after completing the transaction at $0.60 per share. On Mar 17 ’25, another insider, Newton Charles W., who serves as the Chief Financial Officer of the company, bought 200,000 shares for $0.56 each. As a result, the insider paid 111,620 and bolstered with 200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 159777920 and an Enterprise Value of -151781136. For the stock, the TTM Price-to-Sale (P/S) ratio is 2663.00 while its Price-to-Book (P/B) ratio in mrq is 0.42. Its current Enterprise Value per Revenue stands at -2488.215 whereas that against EBITDA is 0.762.
Stock Price History:
The Beta on a monthly basis for LYEL is -0.34, which has changed by -0.75183487 over the last 52 weeks, in comparison to a change of 0.06429911 over the same period for the S&P500. Over the past 52 weeks, LYEL has reached a high of $3.14, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is -11.30%, while the 200-Day Moving Average is calculated to be -50.89%.
Shares Statistics:
LYEL traded an average of 1.03M shares per day over the past three months and 1004040 shares per day over the past ten days. A total of 294.88M shares are outstanding, with a floating share count of 124.87M. Insiders hold about 57.70% of the company’s shares, while institutions hold 22.48% stake in the company. Shares short for LYEL as of 1741910400 were 5977013 with a Short Ratio of 5.79, compared to 1739491200 on 9647386. Therefore, it implies a Short% of Shares Outstanding of 5977013 and a Short% of Float of 2.7199999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
